| abstract |
(S) -pyrrolidine-1,2-dicarboxylic acid 2-amide 1 - ({4- (4-pyridyl) Methyl-5- [2- (2,2,2-trifluoro-1,1-dimethyl-ethyl) -pyridin-4-yl] -thiazol- (B) a pharmaceutical combination comprising at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier; The use of said combination in the treatment of a proliferative disease; And a method of treating a subject suffering from a proliferative disease, comprising administering a therapeutically effective amount of the combination. |